Search

Your search keyword '"Aurrecoechea, Elena"' showing total 142 results

Search Constraints

Start Over You searched for: Author "Aurrecoechea, Elena" Remove constraint Author: "Aurrecoechea, Elena"
142 results on '"Aurrecoechea, Elena"'

Search Results

1. Sex differences in cardiovascular and disease-related features in axial spondyloarthritis. A multicenter study of 912 patients

2. Cardiovascular and disease-related features associated with extra-articular manifestations in axial spondyloarthritis. A multicenter study of 888 patients

3. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

4. SAFETY AND IMMUNOGENICITY OF A PHH-1V BOOSTER DOSE AFTER DIFFERENT PRIME VACCINATION SCHEMES AGAINST COVID-19: PHASE III CLINICAL TRIAL FINAL RESULTS UP TO ONE YEAR

5. Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

6. Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)

7. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice

8. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients

9. O17 SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus, developed from RELESSER prospective database cohort

10. Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

11. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease

12. Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)

15. Sex-specific impact of inflammation on traditional cardiovascular risk factors and atherosclerosis in axial spondyloarthritis. A multicentre study of 913 patients.

17. LP-171 Fibromyalgia and glucocorticoids use drives self-perceived depression in systemic lupus erythematosus: insights from a large prospective and multicenter study using Relesserpros register’s database.

18. Tailoring Rheumatoid Arthritis Treatment through a Sex and Gender Lens.

19. Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA).

20. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients

21. The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses

22. TNF Inhibitors Exert a “Hidden” Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients

28. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients

29. Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases : Results of the Cardiovascular in Rheumatology (Carma) Project

30. TNF Inhibitors Exert a "Hidden" Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients.

31. Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study

32. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

34. Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy

36. Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients

37. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

39. sj-pdf-1-lup-10.1177_0961203320950477 - Supplemental material for Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

40. sj-pdf-2-lup-10.1177_0961203320950477 - Supplemental material for Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

43. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry

44. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

45. SAT0219 EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS INDEPENDENTLY OF THE INICIAL PREDNISONE DOSE

46. FRI0269 COMPARATIVE STUDY OF INFLIXIMAB VERSUS ADALIMUMAB IN REFRACTORY UVEITIS DUE TO BEHÇET’S DISEASE. NATIONAL MULTICENTER STUDY OF 177 CASES

47. FRI0277 ISCHEMIC AND SYSTEMIC SYMPTOMS IN GIANT CELL ARTERITIS PATIENTS, RESPONSE TO TOCILIZUMAB

48. FRI0276 TIME OF DISEASE EVOLUTION AND EFFICACY OF TOCILIZUMAB IN GIANT CELL ARTERITIS

49. AB1077 ANTI-IL6-RECEPTOR TOCILIZUMAB IN GRAVES’ ORBITOPATHY. MULTICENTER STUDY OF 46 PATIENTS IN CLINICAL PRACTICE

50. THU0292 EXTRACRANIAL VESSEL INVOLVEMENT IN PATIENTS WITH GIANT CELL ARTERITIS

Catalog

Books, media, physical & digital resources